The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, L.
Right arrow Articles by Clinton, S. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, L.
Right arrow Articles by Clinton, S. K.

The Journal of Immunology, Vol 159, Issue 1 351-359, Copyright © 1997 by American Association of Immunologists


ARTICLES

Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer

L Chen, D Chen, E Block, M O'Donnell, DW Kufe and SK Clinton
Dana-Farber Cancer Institute, Department of Urology, Harvard Medical School, Boston, MA 02115, USA.

IL-12 is a heterodimeric immunoregulatory cytokine composed of covalently linked p40 and p35 subunits and exhibits antitumor activity in a variety of laboratory models. The efficacy of systemically administered cytokines for cancer therapy is often limited by toxicity. The gene therapy approach provides a mechanism to achieve temporary and high local concentrations of cytokines within a tumor with less risk of systemic toxicity. We constructed replication-defective adenoviruses containing the murine IL-12 p40 subunit (Ad.mp40) or a bicistronic vector containing cDNAs for the p40 and p35 subunits (Ad.mIL-12). Murine MB49 bladder cancer cells infected with Ad.mIL-12 secrete high concentrations of biologically active IL-12, while those infected with Ad.mp40 produce the p40 homodimer. Tumors injected with Ad.mIL-12 show rapid increases in IL-12 and IFN-gamma expression over 2 to 5 days and a return to baseline by 7 to 14 days. Injection of tumors with Ad.mIL- 12 (1 x 10(9) plaque-forming units) results in a complete tumor regression in all mice, while those treated with control adenovirus succumb to their tumor. Efficacy is reduced when studies are performed in mice depleted of CD4+ and CD8+ cells or in nude mice. Mice cured of their tumor by Ad.mIL-12 demonstrate specific protective immunity upon rechallenge. Ad.mp40 does not exhibit antitumor activity and may antagonize the activity of rIL-12 or Ad.mIL-12. In summary, gene therapy strategies for cancer using adenoviral vectors containing IL-12 are highly effective with no significant toxicity in mice.


This article has been cited by other articles:


Home page
J. Immunol.Home page
D.-J. Kim, J.-I. Youn, S.-H. Seo, H.-T. Jin, and Y.-C. Sung
Differential Regulation of Antigen-Specific CD8+ T Cell Responses by IL-12p40 in a Dose-Dependent Manner
J. Immunol., June 1, 2008; 180(11): 7167 - 7174.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Zhu, M. Waguespack, S. A. Barker, and S. Li
Doxorubicin Directs the Accumulation of Interleukin-12 Induced IFN{gamma} into Tumors for Enhancing STAT1 Dependent Antitumor Effect
Clin. Cancer Res., July 15, 2007; 13(14): 4252 - 4260.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. M. Meeran, S. Katiyar, C. A. Elmets, and S. K. Katiyar
Interleukin-12 Deficiency Is Permissive for Angiogenesis in UV Radiation-Induced Skin Tumors
Cancer Res., April 15, 2007; 67(8): 3785 - 3793.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Y.-S. Lee, J.-H. Kim, K.-J. Choi, I.-K. Choi, H. Kim, S. Cho, B. C. Cho, and C.-O. Yun
Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and b7-1 in an immunocompetent murine model.
Clin. Cancer Res., October 1, 2006; 12(19): 5859 - 5868.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. N. Torrero, X. Xia, W. Henk, S. Yu, and S. Li
Stat1 deficiency in the host enhances interleukin-12-mediated tumor regression.
Cancer Res., April 15, 2006; 66(8): 4461 - 4467.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. M. Meeran, S. K. Mantena, S. Meleth, C. A. Elmets, and S. K. Katiyar
Interleukin-12-deficient mice are at greater risk of UV radiation-induced skin tumors and malignant transformation of papillomas to carcinomas.
Mol. Cancer Ther., April 1, 2006; 5(4): 825 - 832.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
Z. Zhou, E. A. Lafleur, N. V. Koshkina, L. L. Worth, M. S. Lester, and E. S. Kleinerman
Interleukin-12 Up-Regulates Fas Expression in Human Osteosarcoma and Ewing's Sarcoma Cells by Enhancing Its Promoter Activity
Mol. Cancer Res., December 1, 2005; 3(12): 685 - 692.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
N. Harada, M. Shimada, S. Okano, T. Suehiro, Y. Soejima, Y. Tomita, and Y. Maehara
IL-12 Gene Therapy Is an Effective Therapeutic Strategy for Hepatocellular Carcinoma in Immunosuppressed Mice
J. Immunol., December 1, 2004; 173(11): 6635 - 6644.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
T. D. Russell, Q. Yan, G. Fan, A. P. Khalifah, D. K. Bishop, S. L. Brody, and M. J. Walter
IL-12 p40 Homodimer-Dependent Macrophage Chemotaxis and Respiratory Viral Inflammation Are Mediated through IL-12 Receptor {beta}1
J. Immunol., December 15, 2003; 171(12): 6866 - 6874.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S.-F. Jia, L. L. Worth, C. L. Densmore, B. Xu, X. Duan, and E. S. Kleinerman
Aerosol Gene Therapy with PEI: IL-12 Eradicates Osteosarcoma Lung Metastases
Clin. Cancer Res., August 1, 2003; 9(9): 3462 - 3468.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
R. Zhang and L. J. DeGroot
Gene Therapy of a Rat Follicular Thyroid Carcinoma Model with Adenoviral Vectors Transducing Murine Interleukin-12
Endocrinology, April 1, 2003; 144(4): 1393 - 1398.
[Abstract] [Full Text] [PDF]


Home page
Physiol. GenomicsHome page
J. C. Fleet, L. Wang, O. Vitek, B. A. Craig, and H. J. Edenberg
Gene expression profiling of Caco-2 BBe cells suggests a role for specific signaling pathways during intestinal differentiation
Physiol Genomics, March 18, 2003; 13(1): 57 - 68.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
L. J. DeGroot and R. Zhang
CLINICAL REVIEW 131: Gene Therapy for Thyroid Cancer: Where Do We Stand?
J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 2923 - 2928.
[Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
T. Maeyama, K. Kuwano, M. Kawasaki, R. Kunitake, N. Hagimoto, and N. Hara
Attenuation of bleomycin-induced pneumopathy in mice by monoclonal antibody to interleukin-12
Am J Physiol Lung Cell Mol Physiol, June 1, 2001; 280(6): L1128 - L1137.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. Kalinski, P. L. Vieira, J. H. N. Schuitemaker, E. C. de Jong, and M. L. Kapsenberg
Prostaglandin E2 is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer
Blood, June 1, 2001; 97(11): 3466 - 3469.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E. A. Lafleur, S.-F. Jia, L. L. Worth, Z. Zhou, L. B. Owen-Schaub, and E. S. Kleinerman
Interleukin (IL)-12 and IL-12 Gene Transfer Up-Regulate Fas Expression in Human Osteosarcoma and Breast Cancer Cells
Cancer Res., May 1, 2001; 61(10): 4066 - 4071.
[Abstract] [Full Text]


Home page
J. Immunol.Home page
W. Li, L. Lu, Z. Wang, L. Wang, J. J. Fung, A. W. Thomson, and S. Qian
IL-12 Antagonism Enhances Apoptotic Death of T Cells Within Hepatic Allografts from Flt3 Ligand-Treated Donors and Promotes Graft Acceptance
J. Immunol., May 1, 2001; 166(9): 5619 - 5628.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
M. J. Walter, N. Kajiwara, P. Karanja, M. Castro, and M. J. Holtzman
Interleukin 12 P40 Production by Barrier Epithelial Cells during Airway Inflammation
J. Exp. Med., February 5, 2001; 193(3): 339 - 352.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Adris, E. Chuluyan, A. Bravo, M. Berenstein, S. Klein, M. Jasnis, C. Carbone, Y. Chernajovsky, and O. L. Podhajcer
Mice Vaccination with Interleukin 12-transduced Colon Cancer Cells Potentiates Rejection of Syngeneic Non-Organ-related Tumor Cells
Cancer Res., December 1, 2000; 60(23): 6696 - 6703.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
K. J. Andrews, A. Ribas, L. H. Butterfield, C. M. Vollmer, F. C. Eilber, V. B. Dissette, S. D. Nelson, P. Shintaku, S. Mekhoubad, T. Nakayama, et al.
Adenovirus-Interleukin-12-mediated Tumor Regression in a Murine Hepatocellular Carcinoma Model Is Not Dependent on CD1-restricted Natural Killer T Cells
Cancer Res., November 1, 2000; 60(22): 6457 - 6464.
[Abstract] [Full Text]


Home page
Clin. Cancer Res.Home page
L. L. Worth, S.-F. Jia, Z. Zhou, L. Chen, and E. S. Kleinerman
Intranasal Therapy with an Adenoviral Vector Containing the Murine Interleukin-12 Gene Eradicates Osteosarcoma Lung Metastases
Clin. Cancer Res., September 1, 2000; 6(9): 3713 - 3718.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
R. Mortarini, A. Borri, G. Tragni, I. Bersani, C. Vegetti, E. Bajetta, S. Pilotti, V. Cerundolo, and A. Anichini
Peripheral Burst of Tumor-specific Cytotoxic T Lymphocytes and Infiltration of Metastatic Lesions by Memory CD8+ T Cells in Melanoma Patients Receiving Interleukin 12
Cancer Res., July 1, 2000; 60(13): 3559 - 3568.
[Abstract] [Full Text]


Home page
BloodHome page
K. Dunussi-Joannopoulos, K. Runyon, J. Erickson, R. G. Schaub, R. G. Hawley, and J. P. Leonard
Vaccines With Interleukin-12-Transduced Acute Myeloid Leukemia Cells Elicit Very Potent Therapeutic and Long-Lasting Protective Immunity
Blood, December 15, 1999; 94(12): 4263 - 4273.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Watanabe, R. G. Fenton, J. M. Wigginton, K. L. McCormick, K. M. Volker, W. E. Fogler, P. G. Roessler, and R. H. Wiltrout
Intradermal Delivery of IL-12 Naked DNA Induces Systemic NK Cell Activation and Th1 Response In Vivo That Is Independent of Endogenous IL-12 Production
J. Immunol., August 15, 1999; 163(4): 1943 - 1950.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
C. Jiang, D. M. Magee, and R. A. Cox
Construction of a Single-Chain Interleukin-12-Expressing Retroviral Vector and Its Application in Cytokine Gene Therapy against Experimental Coccidioidomycosis
Infect. Immun., June 1, 1999; 67(6): 2996 - 3001.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
E. A. Hirschowitz and R. G. Crystal
Adenovirus-Mediated Expression of Interleukin-12 Induces Natural Killer Cell Activity and Complements Adenovirus-Directed gp75 Treatment of Melanoma Lung Metastases
Am. J. Respir. Cell Mol. Biol., May 1, 1999; 20(5): 935 - 941.
[Abstract] [Full Text]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
F. Huaux, C. Lardot, M. Arras, M. Delos, M.-C. Many, J.-P. Coutelier, J.-P. Buchet, J.-C. Renauld, and D. Lison
Lung Fibrosis Induced by Silica Particles in NMRI Mice Is Associated with an Upregulation of the p40 Subunit of Interleukin-12 and Th-2 Manifestations
Am. J. Respir. Cell Mol. Biol., April 1, 1999; 20(4): 561 - 572.
[Abstract] [Full Text]


Home page
Toxicol PatholHome page
B. D. Car, V. M. Eng, J. M. Lipman, and T. D. Anderson
The Toxicology of Interleukin-12: A Review
Toxicol Pathol, January 1, 1999; 27(1): 58 - 63.
[Abstract] [PDF]


Home page
J. Immunol.Home page
N. C. Fernandez, J.-P. Levraud, H. Haddada, M. Perricaudet, and P. Kourilsky
High Frequency of Specific CD8+ T Cells in the Tumor and Blood Is Associated with Efficient Local IL-12 Gene Therapy of Cancer
J. Immunol., January 1, 1999; 162(1): 609 - 617.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
W. M. Siders, P. W. Wright, J. A. Hixon, W. G. Alvord, T. C. Back, R. H. Wiltrout, and R. G. Fenton
T Cell- and NK Cell-Independent Inhibition of Hepatic Metastases by Systemic Administration of an IL-12-Expressing Recombinant Adenovirus
J. Immunol., June 1, 1998; 160(11): 5465 - 5474.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. Gong, D. Chen, M. Kashiwaba, Y. Li, L. Chen, H. Takeuchi, H. Qu, G. J. Rowse, S. J. Gendler, and D. Kufe
Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells
PNAS, May 26, 1998; 95(11): 6279 - 6283.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1997 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1997 by The American Association of Immunologists, Inc. All rights reserved.